(Q35760261)

10 August 2017

Epoetin alfa treatment for acute anaemia during interferon plus ribavirin combination therapy for chronic hepatitis C. (English)

1 reference

10 August 2017

1 reference

1 reference

N Bräu

1

1 reference

10 August 2017

1 May 2004

1 reference

Journal of Viral Hepatitis

10 August 2017

1 reference

10 August 2017

11

1 reference

10 August 2017

191-197

1 reference

10 August 2017

3

1 reference

The prevalence of hepatitis C virus infection in the United States, 1988 through 1994

10 August 2017

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Prevalence of hepatitis C and coinfection with HIV among United States veterans in the New York City metropolitan area

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Long-term liver histology improvement in patients with chronic hepatitis C and sustained response to interferon.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Maintenance therapy with gradual reduction of the interferon dose over one year improves histological response in patients with chronic hepatitis C with biochemical response: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Severe migraine headaches are caused by ribavirin but not by interferon alpha-2B in combination therapy for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

A randomized, controlled trial to determine whether continued ribavirin monotherapy in hepatitis C virus-infected patients who responded to interferon-ribavirin combination therapy will enhance sustained virologic response

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

Histologic improvement of fibrosis in patients with hepatitis C who have sustained response to interferon therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2893.2004.00506.X

10.1111/J.1365-2893.2004.00506.X

21 January 2018

Identifiers

DOI

1 reference

10 August 2017

1 reference

PubMed ID

15117320